<DOC>
	<DOCNO>NCT00002537</DOCNO>
	<brief_summary>Phase I trial study effectiveness radiation therapy plus topotecan treating patient non-small cell lung cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Radiation Therapy Plus Topotecan Treating Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose topotecan chest irradiation patient non-small cell lung cancer . II . Determine qualitative quantitative toxic effect regimen patient . III . Determine degree antitumor activity regimen patient . OUTLINE : This dose escalation study topotecan thoracic radiotherapy . Beginning day 1 , patient receive topotecan IV continuously 3-6 week thoracic radiotherapy 5 day week 2 , 3 , 6 week . Cohorts 4-6 patient receive escalate dos topotecan thoracic radiotherapy maximum tolerate dose ( MTD ) therapy determine . The MTD define dose precede 2 4 6 patient experience dose-limiting toxicity . Six additional patient treat MTD . Patients fail achieve complete remission ( CR ) continue measurable disease 4-6 week completion radiotherapy receive topotecan IV continuously day 1-21 1 dose level precede MTD determine ongoing Protocol NYU-9123 . Treatment continue every 4 week absence unacceptable toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove nonsmall cell lung cancer Eligible chest irradiation 3,000 6,000 cGy ( base upon standard radiotherapy indication ) Measurable evaluable disease Measurable disease define bidimensionally measurable lesion physical exam radiograph ( CT MRI acceptable ) PATIENT CHARACTERISTICS : Age : 18 Performance status : 02 Life expectancy : At least 12 week WBC least 4,000/mm3 Platelet count least 100,000/mm3 Bilirubin great 1.5 mg/dL AST le 3 time normal Alkaline phosphatase less 3 time normal Creatinine great 1.5 mg/dL Not pregnant nursing PRIOR CONCURRENT THERAPY : No 1 prior chemotherapy regimen allow At least 4 week since prior chemotherapy recover No prior radiotherapy Recovered toxic effect prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>